The 201 Trial
This Phase 2 trial is assessing the safety, tolerability and efficacy of IkT-148009 versus a placebo in people with Parkinson’s disease, ages 30-75, who do not currently take anti-Parkinson’s medication.
IkT-148009 is an investigational medication taken by mouth once-daily that targets the underlying biology of Parkinson’s disease, with the goal of halting disease progression and reversing functional loss.
You may qualify if:
- You have been diagnosed with Parkinson’s disease by a neurologist
- You are between the ages of 30-75
- You are not currently taking levodopa or carbidopa (or if you have taken these medications it was for less than a month)
- You have not had any surgery for Parkinson’s disease
For more information about the 201 Trial, and to see if you may qualify, please click HERE or email ResearchNCNE@myneurodr.com / call 781-551-5812 opt.2.